There’s a schism in America’s drug business, playing out in punchy direct messages, feisty group chats, and the occasional heated in-person exchange.
The problem is China. Fledgling startups and pharmaceutical giants alike are addicted to Chinese drugs, filling their pipelines with would-be blockbusters developed at enviable speed and bought on the cheap. They’ve spent some $60 billion on Chinese molecules in the first three months of 2026 alone, according to state figures. That’s on pace to double last year’s total, which was already 10 times larger than the one from 2021.
No one disagrees that it’s good business. And more drugs moving swiftly through development means hope for patients around the world desperately awaiting new medicines.
But, according to more than a dozen interviews with industry executives and investors, the question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another and souring relationships in an otherwise close-knit corporate community.
